FDA Approved: BESPONSA — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)

View source ↗

Summary

The FDA approved a supplemental application for BESPONSA (inotuzumab ozogamicin) submitted by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

SUPPL AP for BESPONSA (INOTUZUMAB OZOGAMICIN)